Bone Biologics Corporation
Bone Biologics Corporation
- Market cap
- $1.47M
Your view on BBLGW
Overview
What the company does, where it operates, and who runs it.
About Bone Biologics Corporation
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jeffrey Frelick
- Headquarters
- 2 Burlington Woods Drive, Burlington, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jeffrey Frelick
- Headquarters
- 2 Burlington Woods Drive, Burlington, MA, US
Bone Biologics Corporation is a medical device firm dedicated to revolutionizing bone regeneration, particularly within spinal fusion procedures. The company's primary innovation is NELL-1/DBX, a unique combination product featuring an osteostimulative recombinant protein.
This bio-engineered protein offers precise, targeted control over new bone formation. Currently, Bone Biologics is advancing the NELL-1/DBX Fusion Device, specifically engineered for spinal fusion applications in skeletally mature patients suffering from degenerative disc disease, focusing on single-level fusions from L4 to S1.
Beyond spinal applications, the versatility of its foundational technology promises to deliver improved outcomes across various surgical disciplines, including general orthopedics, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
Underpinning its development, the company holds a licensing agreement with the UCLA Technology Development Group to further develop and commercialize NELL-1 for spinal fusion. Established in 2004, Bone Biologics Corporation is headquartered in Burlington, Massachusetts.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Bone Biologics Corporation. Starting points for Bone Biologics Corporation: EPS -$0.76, beta 0.53 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Bone Biologics Corporation. Trailing twelve-month EPS for Bone Biologics Corporation stands at -$0.76. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterDec 2026 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|
| Average estimate | −$0.18 | −$1.23 | −$0.67 |
| Lowest estimate | −$0.18 | −$1.23 | −$0.67 |
| Highest estimate | −$0.18 | −$1.23 | −$0.67 |
| Number of analysts | 1 | 1 | 1 |
| A year ago | −$0.581 | −$2.651 | — |
| Growth vs a year ago | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|
| Average estimate | $0.00 | $0.00 | $0.00 |
| Lowest estimate | $0.00 | $0.00 | $0.00 |
| Highest estimate | $0.00 | $0.00 | $0.00 |
| Number of analysts | 0 | 0 | 0 |
| A year ago | $0.00 | $0.00 | — |
| Growth vs a year ago | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Bone Biologics Corporation. Bone Biologics Corporation has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| AMIXAutonomix Medical, Inc. Common Stock | Healthcare | Medical - Devices | $484,136 | ||
| BGMSBio Green Med Solution, Inc. | Healthcare | Medical - Pharmaceuticals | $3.1M | ||
| CNSPCNS Pharmaceuticals, Inc. | Healthcare | Biotechnology | $5.3M | ||
| DHAIDIH Holding US, Inc. | Healthcare | Medical - Devices | — | ||
| HSCSHeartSciences Inc. | Healthcare | Medical - Devices | $9.0M | ||
| MOVEMovano Inc. | Healthcare | Medical - Devices | $103.2M | ||
| RDHLRedHill Biopharma Ltd. | Healthcare | Drug Manufacturers - Specialty & Generic | $883,143 | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| BVNRYBavarian Nordic A/S | Healthcare | OTC | $2.4B | ||
| BXPHFBotanix Pharmaceuticals Limited | Healthcare | OTC | $89.0M | ||
| ARUXFAcrux Limited | Healthcare | OTC | $1.8M | ||
| ARVNArvinas, Inc. | Healthcare | NASDAQ | $423.0M | ||
| ARWRArrowhead Pharmaceuticals, Inc. | Healthcare | NASDAQ | $5.8B | ||
| ASBPAspire Biopharma Holdings, Inc. | Healthcare | NASDAQ | $822,602 | ||
| ASBPWAspire Biopharma Holdings, Inc. | Healthcare | NASDAQ | $121,920 | ||
| ASCLFAscletis Pharma Inc. | Healthcare | OTC | $2.1B | ||
| ASEP.CNAsep Medical Holdings Inc | Healthcare | CNQ | — | ||
| ASMBAssembly Biosciences, Inc. | Healthcare | NASDAQ | $454.4M | ||
| ASNDAscendis Pharma A/S | Healthcare | NASDAQ | $16.6B | ||
| ASPEAspen Neuroscience Inc. | Healthcare | NASDAQ | $361.2M | ||
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Bone Biologics Corporation executives and directors. Shares of Bone Biologics Corporation have traded between $6.80 and $35.95 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Bone Biologics Corporation. Coverage tracks Bone Biologics Corporation within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Bone Biologics Corporation.